Cargando…

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

Aims: Measurement of protein S (PS) activity in patients taking direct oral anticoagulants (DOACs) using reagents based on a clotting assay results in falsely high PS activity, thus masking inherited PS deficiency, which is most frequently seen in the Japanese population. In this study, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terakami, Takako, Nagaya, Satomi, Hayashi, Kenshi, Furusho, Hiroshi, Fujino, Noboru, Kato, Takeshi, Asakura, Hidesaku, Morishita, Eriko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252639/ https://www.ncbi.nlm.nih.gov/pubmed/34334529 http://dx.doi.org/10.5551/jat.62951

Ejemplares similares

Blue Rubber Bleb Nevus Syndrome Complicated by Enhanced-Fibrinolytic-Type DIC: A Case Report
por: Yamada, Shinya, et al.
Publicado: (2021)

Aortic Aneurysm-associated Disseminated Intravascular Coagulation that Responded Well to a Switch from Warfarin to Rivaroxaban
por: Kadohira, Yasuko, et al.
Publicado: (2017)

Recombinant human erythropoietin attenuates hepatic dysfunction by suppressing hepatocellular apoptosis in lipopolysaccharide-induced disseminated intravascular coagulation in rats
por: Suga, Yukio, et al.
Publicado: (2022)

Identification and Prognostication of End-of-Life State Using a Japanese Guideline-Based Diagnostic Method: A Diagnostic Accuracy Study
por: Arahata, Masahisa, et al.
Publicado: (2023)

Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis
por: Horinouchi, Yuya, et al.
Publicado: (2018)

A Case of Treatment With Dabigatran for Cerebral Venous Thrombosis Caused by Hereditary Protein C Deficiency
por: Fukushima, Taiki, et al.
Publicado: (2021)

Protein C Gene Mutation in an Older Adult Patient with Clostridium perfringens Septicemia-Related Visceral Vein Thrombosis
por: Kanosue, Kiyoko, et al.
Publicado: (2021)

Transient swallowing‐induced atrial tachycardia in a patient with genotyped hypertrophic cardiomyopathy
por: Fujino, Noboru, et al.
Publicado: (2020)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Classifying types of disseminated intravascular coagulation: clinical and animal models
por: Asakura, Hidesaku
Publicado: (2014)

Diversity of disseminated intravascular coagulation and selection of appropriate treatments
por: Asakura, Hidesaku
Publicado: (2020)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
por: Burger, Annika, et al.
Publicado: (2023)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities
por: Arahata, Masahisa, et al.
Publicado: (2018)

Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

COVID-19-associated coagulopathy and disseminated intravascular coagulation
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm
por: Yamada, Shinya, et al.
Publicado: (2022)

Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
por: Yamada, Shinya, et al.
Publicado: (2022)

Potential of heparin and nafamostat combination therapy for COVID‐19
por: Asakura, Hidesaku, et al.
Publicado: (2020)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

First report of inherited protein S deficiency caused by paternal PROS1 mosaicism
por: Nagaya, Satomi, et al.
Publicado: (2021)

Distinguishing immune-mediated thrombotic thrombocytopenic purpura from septic disseminated intravascular coagulation using plasma levels of haptoglobin and factor XIII activity
por: Yamada, Shinya, et al.
Publicado: (2023)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Application of Molecular Modeling to Development of New Factor Xa Inhibitors
por: Sulimov, Vladimir B., et al.
Publicado: (2015)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

The Development of New Factor Xa Inhibitors Based on Amide Synthesis
por: Tarasov, Dmitry N., et al.
Publicado: (2018)

Less Is More: Microvascular Thrombophylaxis With Factor-Xa Inhibitor Monotherapy
por: Kotha, Vikas S., et al.
Publicado: (2019)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Factor Xa inhibitors: critical considerations for clinical development and testing
por: Becker, Richard C.
Publicado: (2021)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5qi7dt52crif3vle9326be2q3u